🎉 M&A multiples are live!
Check it out!

Atea Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Atea Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Pharming, and Julphar.

Atea Pharmaceuticals Overview

About Atea Pharmaceuticals

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).


Founded

2012

HQ

United States of America
Employees

56

Website

ateapharma.com

Financials

LTM Revenue n/a

LTM EBITDA -$166M

EV

-$202M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Atea Pharmaceuticals Financials

Atea Pharmaceuticals has a last 12-month revenue of n/a and a last 12-month EBITDA of -$166M.

In the most recent fiscal year, Atea Pharmaceuticals achieved revenue of n/a and an EBITDA of -$193M.

Atea Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Atea Pharmaceuticals valuation multiples based on analyst estimates

Atea Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$164M -$193M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$116M -$136M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Atea Pharmaceuticals Stock Performance

As of April 15, 2025, Atea Pharmaceuticals's stock price is $3.

Atea Pharmaceuticals has current market cap of $251M, and EV of -$202M.

See Atea Pharmaceuticals trading valuation data

Atea Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$202M $251M XXX XXX XXX XXX $-1.92

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Atea Pharmaceuticals Valuation Multiples

As of April 15, 2025, Atea Pharmaceuticals has market cap of $251M and EV of -$202M.

Atea Pharmaceuticals's trades at n/a LTM EV/Revenue multiple, and 1.2x LTM EBITDA.

Analysts estimate Atea Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Atea Pharmaceuticals and 10K+ public comps

Atea Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$202M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 1.0x XXX XXX XXX
P/E -1.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Atea Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Atea Pharmaceuticals Valuation Multiples

Atea Pharmaceuticals's NTM/LTM revenue growth is Infinity%

Atea Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $3.4M for the same period.

Over next 12 months, Atea Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Atea Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Atea Pharmaceuticals and other 10K+ public comps

Atea Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 18% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $3.4M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Atea Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Atea Pharmaceuticals M&A and Investment Activity

Atea Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Atea Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Atea Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Atea Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Atea Pharmaceuticals

When was Atea Pharmaceuticals founded? Atea Pharmaceuticals was founded in 2012.
Where is Atea Pharmaceuticals headquartered? Atea Pharmaceuticals is headquartered in United States of America.
How many employees does Atea Pharmaceuticals have? As of today, Atea Pharmaceuticals has 56 employees.
Who is the CEO of Atea Pharmaceuticals? Atea Pharmaceuticals's CEO is Dr. Jean-Pierre Sommadossi,PhD.
Is Atea Pharmaceuticals publicy listed? Yes, Atea Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Atea Pharmaceuticals? Atea Pharmaceuticals trades under AVIR ticker.
When did Atea Pharmaceuticals go public? Atea Pharmaceuticals went public in 2020.
Who are competitors of Atea Pharmaceuticals? Similar companies to Atea Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Atea Pharmaceuticals? Atea Pharmaceuticals's current market cap is $251M
What is the current EBITDA of Atea Pharmaceuticals? Atea Pharmaceuticals's last 12-month EBITDA is -$166M.
What is the current EV/EBITDA multiple of Atea Pharmaceuticals? Current EBITDA multiple of Atea Pharmaceuticals is 1.2x.
Is Atea Pharmaceuticals profitable? Yes, Atea Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.